EPIRUS Biopharma (EPRS) Tops Q4 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
EPIRUS Reports Fourth Quarter and Fiscal Year 2014 Financial Results
March 23, 2015 4:35 PM EDTBOSTON, March 23, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014.
"In 2014, we became a publicly listed company and a commercial-stage company with the launch of our lead product candidate,... More
EPIRUS Reports Fourth Quarter and Fiscal Year 2014 Financial Results
March 23, 2015 4:35 PM EDTBOSTON, March 23, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014.
"In 2014, we became a publicly listed company and a commercial-stage company with the launch of our lead product candidate,... More
